Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin®
(trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2
positive and hormone-receptor positive metastatic breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Prof. W. Janni
Collaborators:
Celgene Corporation DETECT study group Eisai GmbH Novartis Pharmaceuticals Roche Pharma AG